To identify the recent data regarding prevalence, incidence, survival, and risk factors for systemic sclerosis (SSc) and to compare these data to previously published findings.
INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by small vessel vasculopathy, autoantibody production, and excessive collagen deposition in the skin and internal organs [1] . The classification of SSc is divided into two groups: limited and diffuse cutaneous disease [2] . The limited form is characterized by thickening of the skin confined to the areas distal to the elbows and knees, and is associated with less severe internal organ involvement. The diffuse form involves skin thickening proximal to the elbows and knees in addition to distal area involvement and is associated with more severe organ damage. This review will focus on the epidemiology of SSc and discuss the recently published articles related to this topic. The incidence and prevalence, survival, risk factors, malignancy, and putative environmental triggers will be reviewed.
INCIDENCE AND PREVALENCE OF SYSTEMIC SCLEROSIS
Previously reported incidence and prevalence estimates vary greatly according to geographic location and methods of case ascertainment. Classification criteria were not developed until 1980 when the American Rheumatism Association (now the American College of Rheumatology, ACR) proposed criteria to distinguish SSc from other connective tissue diseases [3] . Table 1 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] They reported an improvement in survival from 54% in the 1970s to 66% in the 1990s. The improvement in survival was attributed to improvement in diagnosis (lead time bias) and the implementation of effective therapy for scleroderma renal crisis. They found that pulmonary fibrosis and pulmonary arterial hypertension supplanted scleroderma renal crisis as the leading causes of death in SSc-related mortality (Table 2) .
Recently, the causes and risk factors for death in SSc were reported by the European League against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) database [26 && ]. The database included 5860 SSc patients who fulfilled the ACR 1980 classification criteria. Causes of death and comorbidity data were available from 234 of 284 fatalities. Using a multivariate Cox proportional hazards model to calculate predictors of mortality, they reported that 55% of deaths were directly related to SSc and 41% to non-SSc causes with the remaining 4% of cases considered nonclassifiable.
Among the 284 deceased patients, 54.6% had diffuse cutaneous disease (dcSSc) and 40.5% had limited cutaneous disease (lcSSc). The median disease duration was 7.1 years for dcSSc and 15 years for lcSSc. 19% died of pulmonary fibrosis and 14% of pulmonary arterial hypertension. SSc-related myocardial disease death was 14% with most causes being related to arrhythmias. Renal causes of death only accounted for 4%, all of which were related to scleroderma renal crisis. Three percentage of patients died from gastrointestinal-related causes.
With respect to the non-SSc-related deaths, causes were as follows: infections (13% of all deaths), neoplasia (13%), and cardiovascular disease (12%). Patients with non-SSc-related deaths were then analyzed for SSc-related comorbidities. A significant number of patients who died from pneumonia also had presence of gastroesophageal reflux with or without documented aspiration. Of the fourteen patients who died from lung cancer, nine had concomitant pulmonary fibrosis. In this study, independent predictors of reduced survival included presence of proteinuria, pulmonary arterial hypertension, pulmonary restriction with a forced vital capacity of less than 80% predicted, presence of dyspnea greater than New York Heart Association Class II, higher age at onset of Raynaud's phenomenon, lower diffusion capacity for carbon monoxide, and a modified Rodman skin score greater than 10. This report reinforced the previous finding that pulmonary fibrosis and pulmonary arterial hypertension are the leading causes of SSc-related deaths and likely contribute to non-SSc-related deaths.
In addition, a population-based South Australian registry reported survival in 786 scleroderma patients using standardized mortality ratios compared with the general population [27 & ]. As expected, SSc patients had decreased survival compared with a standardized mortality ratio of 1.46 [95% confidence interval (CI) 1.28-1.69]. Factors that increased mortality in this study were older age of onset, male sex, scleroderma renal crisis, pulmonary fibrosis, pulmonary arterial hypertension, cancer, and antitopoisomerase and anti-U1 antibodies. In a systematic review of the possible association of silicone breast implants and SSc, Lipworth et al. [31] confirmed that there was no association.
RISK FACTORS
Previously reported risk factors for the development of SSc include sex, race, age, family history, birth order, and genetic factors. As noted above in recent incidence and prevalence data, women considerably outnumber men.
In terms of race/ethnicity, African-Americans have been reported to have earlier onset and more severe disease. Nashid et al. [32 & ] collected data from three randomized clinical treatment trials to evaluate sex and ethnicity differences. Their report included 495 patients of which 81.4% were women, 71.1% were non-Hispanic Caucasian, 16% were African-American, 9.5% were Hispanic, and 3.4% belonged to another category (Asian and unknown). On average, men had higher serum creatinine, hematocrit, and creatine phosphokinase (CPK). However, functional quality of life as assessed by the Health Assessment Questionnaire with Disability Index (HAQ-DI) was lower (better) in men than in women. On average, Caucasian patients were older than African-American and Hispanic patients. African-American patients had higher CPK levels and worse pulmonary function than the other two groups. Hispanic patients had more tender joints compared with the other groups. The course of skin disease and percentage predicted forced vital capacity did not differ between sex and ethnicities.
Another study by Manno et al. [33 & ] evaluated the age of onset and the severity of disease. The group hypothesized that later-age onset SSc would have a different risk for specific organ manifestations. They evaluated 2300 SSc patients from 1990 to 2009 from the Johns Hopkins Scleroderma Center, defining SSc based on the LeRoy-Medsger criteria. Of the 2300 patients, 216 had disease onset at at least 65 years. A higher proportion of these lateonset patients had anticentromere antibodies than did their younger counterparts. The risk of pulmonary hypertension, muscle weakness, renal impairment, and cardiac disease was greater among the late-onset patients. However, the risk of digital ischemia was reduced in this group. There was no difference in the prevalence of scleroderma renal crisis between the groups.
Genetic risk factors have been studied by several groups. In the past year, Nguyen et al. [34] reported HLA markers that have a predictive role in scleroderma renal crisis. They included 1519 SSc patients, 90 of whom had scleroderma renal crisis. These authors found that HLA-DRB1Ã0407 and HLA-DRB1Ã1304 are risk factors for renal crisis independently of clinical variables. Similarly to previous studies, they confirmed that diffuse cutaneous involvement and anti-RNA polymerase III antibodies were also risk factors for scleroderma renal crisis.
A large genome-wide association study (GWAS) by Gorlova et al. [35 & ] identified genetic components contributing to the different clinical subphenotypes of SSc. Analyzing a total of 2296 SSc cases and 5171 healthy controls and confirmed in an independent group of 3175 SSc cases and 4971 controls, they found that disease susceptibility as well as disease severity are influenced by genetic factors including both the HLA/MHC region as well as non-MHC loci.
MALIGNANCY
In the past, several studies have studied the association of malignancy and scleroderma with sometimes conflicting findings [36 & ].
In a recent Danish study from a national registry in the period 1997-2006, Olesen et al. [37] found 222 cases of cancer identified after the diagnosis of SSc. These authors reported an increased standardized incidence ratio for cancer of 1.5. Men had a higher incidence of cancer than women with a standardized incidence ratio of 2.2 (95% CI 1.7-2.8) for men and 1.3 (95% CI 1.1-1.6) for women. The most frequent malignancies reported were smokingrelated and alcohol-related cancers.
Another cohort study in southwest England by Siau et al. [36 & ] studied malignancy in SSc patients and age-matched controls based on a regional healthcare database. They identified 15 malignancies out of 68 SSc patients. Although the total number of SSc cases was low, the authors calculated a relative risk of 3.15 (95% CI 1.77-5.20) in overall cancers and found the highest to be hematologic malignancies.
CONCLUSION
Over the past years, there have been several studies regarding incidence and prevalence of SSc. The reported studies continue to show variation by geographic region. Incidence rates and prevalence estimates are fairly similar for Europe, the United States, Australia, and Argentina suggesting a prevalence of 150-300 cases per million with a lower prevalence noted in Scandinavia, Japan, the UK, Taiwan, and India.
Although survival rates have improved over time, pulmonary fibrosis and pulmonary arterial hypertension continue to be the leading causes of SSc-related deaths. In all studies, SSc is more common in women than in men and the cause of this discrepancy remains speculative. African-American (US study) and older age onset (multiple countries) patients have more severe disease.
This past year has seen new evidence for the role of genetic factors in SSc occurrence and disease severity, particularly scleroderma renal crisis. The association of autoantibodies with particular disease manifestation has been further validated.
Although there is evidence to suggest an association between environmental exposures and SSc, such exposures only contribute to a small proportion of all cases. Cigarette smoking was not found to increase the risk of developing SSc but appears to contribute to disease severity. It is likely that there is an increased risk of cancer among SSc patients, but reports vary about the magnitude of this risk and the type of malignancy. This adds to the literatures of incidence and prevalence in Latin American countries and is important because it has not been reported on until this year. 23.
